ASH: Roche un­corks eye­pop­ping re­spons­es in bis­pe­cif­ic test, hop­ing to add a jew­el to its fu­ture port­fo­lio

In a heat­ed race with some of phar­ma’s biggest play­ers, Roche’s Genen­tech is look­ing to dri­ve a lead bis­pe­cif­ic an­ti­body pro­gram through the clin­ic against stub­born blood can­cers. As the field watch­es close­ly, Roche is now trot­ting out da­ta it thinks could earn its drug a first shot at the mar­ket.

Roche’s mo­sune­tuzum­ab, a bis­pe­cif­ic tar­get­ing the CD20 pro­tein on the sur­face of tu­mors and the CD3 pro­tein on T cells, post­ed a 60% com­plete re­sponse rate, ac­cord­ing to da­ta from near­ly 100 pa­tients with third-line-or-lat­er fol­lic­u­lar lym­phoma in an open-la­bel, sin­gle-arm Phase I/II study dubbed GO29781 pre­sent­ed Sat­ur­day at #ASH21.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN